secwatch.observer — SEC 8-K summary
======================================

Issuer:     Structure Therapeutics Inc. (GPCR)
CIK:        0001888886
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001104659-24-087275
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Structure Therapeutics Q2 net loss $26M; cash $927M; GSBR-1290 Phase 2b on track Q4 2024
--------------------------------------------------------------------------------

- Q2 2024 net loss $26.0M vs $23.3M in Q2 2023; R&D expenses $22.1M, G&A $11.3M.
- Cash, equivalents and short-term investments $927.1M expected to fund operations through at least 2027.
- GSBR-1290 Phase 2b obesity study on track to initiate in Q4 2024; Phase 2a showed 6.2% placebo-adjusted weight loss at 12 weeks.
- Amylin receptor agonist development candidate expected to be selected in Q4 2024; GIPR candidate expected H1 2025.
- Phase 1 trial of LTSE-2578 (LPA1R antagonist for IPF) initiated in June 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1888886/000110465924087275/0001104659-24-087275-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1888886/000110465924087275/tm2421118d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-087275

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer